Chinese cell therapy biotech company Shanghai Cell Therapy Group Co. has raised RMB275 million (US$39.60 million) in series C1 round of financing from private equity firm China Industrial Asset Management Limited.  The latest round also saw the participation from Legend Capital. China Industrial Asset Management Limited has contributed RMB180 million (US$25.92 million) to the round of […]

Chinese Private Equity China Industrial Asset Management Leads $40M Series C1 Round In Cancer Immunotherapy Company appeared first on China Money Network.